If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 221 - 230 of 269
A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
Objective
A Phase 1b 2 Study of MK-6070 and I-DXd in Patients with RR Extensive Stage SCLC
Protocol No
MERCK-MK-6070-002
Categories
A Phase 3, Two-Part, Randomized, Open-Label, Adaptive Study Comparing BMS-986365 Versus a Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Objective
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer (rechARge)
Protocol No
BMS-CA071-1000-RECHARGE
Categories
Self-Sampling to Optimize Anal Lesion Outcomes (SOLO) Protocol
Objective
Self-sampling to Optimize Anal Lesion Outcomes
Protocol No
IIT-NYITRAY-SOLO
Categories
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
Objective
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Protocol No
ALLIANCE-A012303-SHORTSTOP
Categories
Precision Neuromodulation in Post-Stroke Aphasia Using TMS
Objective
Post-Stroke Aphasia TMS - TaMS
Protocol No
NEURO-IIT-SHAH-TAMS
Categories
A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis
Objective
Best Available Therapy vs Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis
Protocol No
NEURO-ITN-077I-BEAT-MS
A Phase 3 Randomized, Open-Label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Next-Generation Hormonal Agent (NHA) and Tax
Objective
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Protocol No
MERCK-MK-5684-003
Categories
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Objective
Testing the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy after surgical removal of the bladder for bladder cancer treatment.
Protocol No
ALLIANCE-A032103-MODERN
Categories
A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-Targeting Human Antibody-Cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-Line Therapy in Patients with Metastatic Leiomyosarcoma
Objective
L19TNF treatment of metastatic soft tissue sarcoma patients
Protocol No
PHILOGEN-PH-L19TNFDOX2-02-17
A Phase 1b/2, Open-Label, Dose Finding and Expansion Study of BGB-16673 in Combination with Other Agents in Relapsed or Refractory B-Cell Malignancies
Objective
Study of BGB-16673 in combination with other agents for patients with R/R B-cell malignancies
Protocol No
BEIGENE-BGB-16673-104
Categories